Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Neuro-oncology

A step towards clinical blood biomarkers of glioblastoma

Nature Reviews Neurology volume 10, pages 681–682 (2014)Cite this article

Subjects

Glioblastoma is the most common primary brain tumour in adults, but—unlike many other cancers—no blood-based biomarkers are available for differential diagnosis, estimation of prognosis or monitoring of treatment response in glioblastoma. New research has detected three proteins with potential clinical value in the blood of patients with glioblastoma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ilhan-Mutlu, A., Wagner, L. & Preusser, M. Circulating biomarkers of CNS tumors: an update. Biomark. Med. 7, 267–285 (2013).

    Article  CAS  Google Scholar 

  2. Gallego Perez-Larraya, J. et al. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer http://dx.doi.org/10.1002/cncr.28949.

  3. Ilhan-Mutlu, A. et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg. Rev. 36, 45–55 (2013).

    Article  Google Scholar 

  4. Brommeland, T., Rosengren, L., Fridlund, S., Hennig, R. & Isaksen, V. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol. Scand. 116, 380–384 (2007).

    Article  CAS  Google Scholar 

  5. Jung, C. S. et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130, 3336–3341 (2007).

    Article  CAS  Google Scholar 

  6. Muller, C. et al. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 6, 247ra101 (2014).

    Article  Google Scholar 

  7. Bernardi, D. et al. Serum YKL-40 following resection for cerebral glioblastoma. J. Neurooncol. 107, 299–305 (2012).

    Article  CAS  Google Scholar 

  8. Prakash, M. et al. Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling. Cell. Signal. 25, 1567–1573 (2013).

    Article  CAS  Google Scholar 

  9. Baxter, R. C. IGF binding proteins in cancer: mechanistic and clinical insights. Nat. Rev. Cancer 14, 329–341 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria

    Matthias Preusser

Authors
  1. Matthias Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Preusser.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Preusser, M. A step towards clinical blood biomarkers of glioblastoma. Nat Rev Neurol 10, 681–682 (2014). https://doi.org/10.1038/nrneurol.2014.208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.208

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer